Page last updated: 2024-12-07

cyclic adp-ribose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cyclic ADP-Ribose: A pyridine nucleotide that mobilizes CALCIUM. It is synthesized from nicotinamide adenine dinucleotide (NAD) by ADP RIBOSE CYCLASE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123847
CHEBI ID31445
SCHEMBL ID21437128
MeSH IDM0162860

Synonyms (28)

Synonym
cyclic adp ribose
gtpl2445
(2r,3r,4s,5r,13r,14s,15r,16r)-3,4,8,10,14,15-hexahydroxy-24-imino-7,9,11,25,26-pentaoxa-1,17,19,22-tetraaza-8$l^{5},10$l^{5}-diphosphapentacyclo[18.3.1.1^{2,5}.1^{13,16}.0^{17,21}]hexacosa-18,20,22-triene-8,10-dione
cadpr
cyclic adp-ribose
119340-53-3
unii-q780br06v8
q780br06v8 ,
capd ribose
e-nad
adenosine 5'-(trihydrogen diphosphate), n-alpha-d-ribofuranosyl-, intramol. 5'-5'-ester
CHEBI:31445
cyclic adp-d-ribose
adenosine 5'-(trihydrogen diphosphate), n-.alpha.-d-ribofuranosyl-, intramol. 5'-5'-ester
J-004109
cadp-ribose (cadpr)
(2r,3r,4s,5r,8s,10r,13r,14s,15r,16r,24e)-24-imino-7,9,11,25,26-pentaoxa-1,17,19,22-tetraaza-8,10-diphosphapentacyclo[18.3.1.1~2,5~.1~13,16~.0~17,21~]hexacosa-18,20,22-triene-3,4,8,10,14,15-hexol 8,10-dioxide (non-preferred name)
(2r,3r,4s,5r,13r,14s,15r,16r)-8,10-dihydroxy-24-imino-8,10-dioxo-7,9,11,25,26-pentaoxa-1,17,19,22-tetraza-8lambda5,10lambda5-diphosphapentacyclo[18.3.1.12,5.113,16.017,21]hexacosa-18,20,22-triene-3,4,14,15-tetrol
BQOHYSXSASDCEA-KEOHHSTQSA-N
DTXSID50896995
Q27459000
SCHEMBL21437128
Q2467043
CS-0119339
cyclic adp-?ribose
HY-N7395
cyclic adenosine 5'-diphosphate ribose ammonium salt
AKOS040744206

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Both 2'-P-cADPR and cADPR appear to act by a similar mechanism based on similar kinetics of Ca2+ release, similar dose-response curves, cross-desensitization, and partial inhibition of release by procaine."( 2'-Phospho-cyclic ADP-ribose, a calcium-mobilizing agent derived from NADP.
Chen, CS; Jacobson, MK; Lu, PJ; Vu, CQ, 1996
)
0.68
" Dose-response curves on the production of inositol-1,4,5-trisphosphate and Ca2+ by ATP and UTP were consistently similar."( Expression cloning and signal transduction pathway of P2U receptor in mammary tumor cells.
Enomoto, K; Furuya, K; Maeno, T; Moore, RC; Oka, T; Yamagishi, S,
)
0.13
"5 microm) of cADPR shifted the dose-response curve of caffeine-induced 45Ca2+ release to the left."( Characterization of ryanodine-sensitive Ca2+ release from microsomal vesicles of rat parotid acinar cells: regulation by cyclic ADP-ribose.
Nishiyama, A; Ozawa, T, 1997
)
0.5
" The presence of exogenously added CaM (10 microg/ml) markedly increased the caffeine (5-10 mM)-induced (45)Ca(2+) release and shifted the dose-response curve of caffeine-induced (45)Ca(2+) release to the left."( Ryanodine-sensitive Ca(2+) release mechanism of rat pancreatic acinar cells is modulated by calmodulin.
Ozawa, T, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
ryanodine receptor agonistA ryanodine receptor modulator which activates the receptor. Ryanodine receptors (RyRs) act as selective ion channels, modulating the release of calcium. Activating the receptors causes the release of calcium, so depleting internal calcium and ultimately preventing further muscle contraction.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
cyclic purine nucleotide
nucleotide-sugar
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
NAD+ Signalling Pathway (Cancer)1012
Airway smooth muscle cell contraction15
Cell-type dependent selectivity of CCK2R signaling06

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1346628Human TRPM2 (Transient Receptor Potential channels)2006FASEB journal : official publication of the Federation of American Societies for Experimental Biology, May, Volume: 20, Issue:7
Nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose regulate TRPM2 channels in T lymphocytes.
AID1346628Human TRPM2 (Transient Receptor Potential channels)2005Molecular cell, Apr-01, Volume: 18, Issue:1
Cyclic ADP-ribose and hydrogen peroxide synergize with ADP-ribose in the activation of TRPM2 channels.
AID1346628Human TRPM2 (Transient Receptor Potential channels)2006The EMBO journal, May-03, Volume: 25, Issue:9
TRPM2 activation by cyclic ADP-ribose at body temperature is involved in insulin secretion.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (737)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.14)18.7374
1990's253 (34.33)18.2507
2000's321 (43.55)29.6817
2010's125 (16.96)24.3611
2020's37 (5.02)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.87 (24.57)
Research Supply Index6.63 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index43.75 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews127 (16.75%)6.00%
Case Studies2 (0.26%)4.05%
Observational0 (0.00%)0.25%
Other629 (82.98%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]